We are pleased to invite you to an exclusive, invitation-only investor reception on Wednesday, October 8 in Palo Alto featuring i-Lumen Scientific, a ophthalmology company focused on restoring vision in those Dry Age-related Macular Degeneration (Dry-AMD).

Please note that this meeting is for DIRECT and ACTIVE investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval.

Unlike current pharma-based therapies that merely slow disease progress (vision loss), i-Lumen’s patented, non-invasive ocular stimulation therapy (OST) is designed to improve vision with a ‘physician-delivered therapy’ to help the 200.0M people worldwide suffering from Dry-AMD. i-Lumen’s recently completed i-SIGHT Study demonstrated that 54% of participants had improved vision of 2+ Lines (10+ letters) within 7 treatment days delivered within 2 months and maintained the improvement through 12 months.

With a large unmet market, strong clinical data, and a clear FDA pathway, i-Lumen is positioned to be acquired by a strategic in Ophthalmology as early as 2028, and the $850.0M acquisition of LumiThera by Alcon in 2025 has established a benchmark for energy-based therapeutics to treat Dry-AMD.

Please tap on the link to learn more about the i-Lumen’s AMD System i-Lumen Scientific – Retinal Bio-stimulation Therapy for Dry AMD.

The Investment Opportunity:

• Series B raise: $35.0M, with $18.0M committed from Series A Investors
• Valuation: $31.5M pre-money / $69.3M post-money
• Investment Options: Direct – $500K, SPV – $100K

• Use of funds: Pivotal Study, FDA filing, Commercial Readiness

Why Attend

Superior Mechanism of Action Restores Vision

i-Lumen’s proprietary ocular stimulation therapy repolarizes retinal pigment epithelium (RPE) cells and restores photoreceptor cell function, improving visual acuity and slowing disease progression.

• 54% improved BCVA by ≥10 letters and maintained improvement out to 12 mths
• 21% increase in photoreceptor cell light-processing speed
• 14% increase in signal strength generated by photoreceptor cells

Massive, Underserved Market

• 200.0 M people globally suffer with AMD, more than 20.0M in the US alone
• Dry AMD market projected to be $68.0B by 2029

Established Acquisition Benchmark – $850.0M Pre-Revenue Sale

• Alcon acquired LumiThera, Inc. for an estimated $850.0M
• LumiThera’s Velada® is an energy-based device therapy for dry AMD

The LumiThera acquisition underscores the industry’s focus on energy-based therapies like the i-Lumen® AMD System, a scalable physician-based revenue model

Pathway to Exit in 2028

• i-SIGHT2 Pivotal Trial data availability – projected for mid-2027
• Submission to FDA for market clearance – projected for late 2027
• Re-engage ophthalmology targets (Alcon, B+L, J&J, etc.) – projected for 2028

Why Attend:

This is a rare opportunity to invest in a late-stage ophthalmology company with a therapeutic that generates vision improvement an industry known for pre-revenue acquisitions. With validated science, a de-risked FDA strategy, and strong IP, i-Lumen offers the potential for 12–15x return projected within the next 2 to 3 years.

Join us for an insider’s view into how i-Lumen is creating a paradigm shift in vision restoration and meet the leadership team powering this transformation.

Event Details:

Fleming’s Prime Steakhouse & Wine Bar,

180 El Camino Real G-2,

Palo Alto, CA 94304

October 8, 2025 | 5:30 PM PDT

RSVP now to secure your seat and request investor materials by contacting: Skylar Rallison at srallison@opus8.com

We look forward to seeing you in Palo Alto for an evening of groundbreaking science, strategic vision, and investment opportunity.

We will provide a confirmation email and a calendar invitation after you register.

Your attendance will be subject to client review and availability.

Thanks much and all the best,

The Opus8 Team